1:47
Why children should be offered choices in their treatment plans
Imelda Coyne
1:41
Why it is important to involve children and adolescents in treatment decision-making
Imelda Coyne
2:52
The role of proteasome inhibitors in multiple myeloma
Mohamad Mohty
3:11
Information is key: why patients need to be empowered to learn about their disease
John Murray
2:15
Assessment of response in multiple myeloma: next steps
Bruno Paiva
2:27
Highlights from EBMT 2016: Immunotherapy
Arnon Nagler
2:30
FLT3 inhibitors – their role in AML
Ali Bazarbachi
1:34
Next steps for novel treatments in multiple myeloma
Bruno Paiva
2:44
The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
Chiara Bonini
1:49
Drugs vs transplants in acute leukemias
Arnon Nagler
2:48
Virus-specific T cells – effectiveness, safety profile and use
Ann Leen
1:39
The significance of FLT3 mutations in AML
Ali Bazarbachi
3:35
Assessment of response in MM: challenges and advances
Bruno Paiva
2:30
Matched unrelated donor (MUD) transplantations for ALL and AML
Arnon Nagler
3:22
CAR T-cells and fast cars
Antonio Pagliuca
1:14
‘Off the shelf’ virus-specific T cells
Ann Leen
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals